Nikhil Prasad Fact checked by:Thailand Medical News Team May 19, 2026 49 minutes ago
Medical News: Researchers are now investigating whether a drug currently used for psychiatric disorders could also help block Ebola virus infections. A new computational study has found that Lumateperone, a medication approved for schizophrenia and bipolar depression, may interfere with the Ebola virus’s ability to enter human cells.
Researchers find that Lumateperone may weaken the Ebola virus’s ability to attach to and infect human cells
The study was carried out by scientists from the Gomal Center of Biochemistry and Biotechnology at Gomal University in Pakistan, the Department of Biological Sciences and the Princess Dr Najla Bint Saud Al-Saud Center for Excellence Research in Biotechnology at King Abdulaziz University in Saudi Arabia, the Department of Human Genetics at Sidra Medicine in Qatar, and the Department of Public Health at Daffodil International University in Bangladesh.
Ebola Remains One of the World’s Deadliest Viruses
Ebola virus disease continues to pose a major global health threat because of its extremely high fatality rates and the limited number of effective treatments available. The virus attacks the body aggressively, causing severe bleeding, organ damage, immune dysfunction, and often death.
To infect humans, Ebola relies on a special surface structure called the spike protein or S-protein. This viral protein attaches itself to a receptor found on human cells known as TIM-1. Once the virus successfully binds to TIM-1, it can enter the cell and begin replicating rapidly.
Because of this, scientists have been searching for ways to block the interaction between the Ebola S-protein and the TIM-1 receptor.
Researchers Used Advanced Computer Modeling
In the new study, researchers used molecular docking and simulation technologies to examine whether Lumateperone could bind to either the Ebola S-protein or the TIM-1 receptor strongly enough to interrupt viral entry.
The findings showed that Lumateperone displayed strong attraction to both the viral protein and the human receptor. More importantly, the drug appeared capable of destabilizing the bond formed between them.
Under normal conditions, the binding energy between the Ebola S-protein and the TIM-1 receptor measured approximately 900 kJ/mol. However, when Lumateperone was introduced into the simulation, the binding energy decreased sharply.
Researchers observed a reduction of approximately 395.75 kJ/mol when Lumateperone first attached to the viral S-protein. When the drug initially attached to the TIM-1 receptor, the reduction reached approximately 517.19 kJ/mol.
This significant drop suggested that the virus-receptor complex became much less stable in the presence of the drug, potentially making it harder for Ebola to infect cells.
Key Viral Entry Sites Were Targeted
One of the most important discoveries was that Lumateperone interacted with several crucial residues involved in Ebola infection.
The drug bound to Asn461 on the Ebola S-pro
tein and also attached to Trp274 and Asn275 on the TIM-1 receptor. These specific sites are believed to play important roles during viral attachment and entry into human cells.
Researchers noted that Lumateperone appeared to occupy some of the same interaction regions normally used by the virus to establish contact with human cells. This suggests the drug may physically interfere with Ebola’s ability to gain entry.
Simulations Showed the Complex Became Unstable
The team also performed molecular dynamic simulations to study how stable the Ebola-TIM-1 complex remained after Lumateperone binding.
The simulations demonstrated that the complex became increasingly unstable and easier to deform in the presence of the drug. Scientists observed low eigenvalues and reduced stiffness within the molecular structure, both signs that the viral attachment system had weakened considerably.
This
Medical News report highlights that the research was entirely computational and has not yet been confirmed in laboratory or clinical studies. However, the findings offer an encouraging starting point for future antiviral research.
Existing Drug Could Speed Up Ebola Research
One major advantage of Lumateperone is that it is already an approved medication with established pharmacological and safety data. Repurposing existing drugs can dramatically shorten the time needed to develop potential therapies during outbreaks.
The researchers also pointed out that compounds related to Lumateperone have previously shown antiviral properties against viruses such as Epstein-Barr virus, hepatitis B virus, and even coronavirus-related targets.
Conclusion
The study provides compelling early evidence that Lumateperone may help block Ebola virus infection by interfering with the critical interaction between the viral spike protein and the TIM-1 receptor on human cells. By weakening this attachment process, the drug could potentially reduce the virus’s ability to invade and spread inside the body. Although the findings remain limited to computer-based simulations, the results are scientifically significant because they identify a previously unrecognized antiviral potential for an already approved drug. Researchers stress that laboratory experiments and clinical investigations are now urgently needed to determine whether these promising computational findings can translate into real-world Ebola treatments.
The study findings were published in the peer reviewed journal: Applied Sciences.
https://www.mdpi.com/2076-3417/12/17/8820
For the latest Ebola news, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/pink-rockrose-compounds-show-promise-against-ebola
https://www.thailandmedical.news/news/old-gout-drug-shows-promise-against-ebola
https://www.thailandmedical.news/news/study-finds-that-berberine-hydrochloride-could-be-used-to-inhibit-ebola-virus
https://www.thailandmedical.news/news/the-phytochemical-kolaviron-from-garcinia-kola-bitter-kola-shows-potential-against-the-ebola-virus-further-studies-needed
https://www.thailandmedical.news/news/u-s-nih-study-finds-that-algal-lectin-griffithsin-shows-promise-in-preventing-ebola-virus-infection
Medical Disclaimer: All content published by Thailand Medical News is based on scientific research and is intended for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Readers must not attempt to use, apply, or experiment with any protocols, compounds, or therapies mentioned without first consulting a qualified and licensed medical doctor. Many findings discussed are experimental or preliminary, and only a licensed healthcare professional can determine what is safe and appropriate for an individual’s specific medical condition.
Share
Tweet
Share
